|Bid||0.0200 x N/A|
|Ask||0.0250 x N/A|
|Day's Range||0.0150 - 0.0250|
|52 Week Range||0.0150 - 0.1000|
|Beta (5Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Corporation is continuing to work diligently and expeditiously to complete the Interim Filings and expects to file the Interim Filings on or prior to the extended deadline of July 16, 2020. Until such time as the Interim Filings are filed, Elixxer’s management and other insiders will continue to be subject to a trading black-out that reflects the principles in Section 9 of Policy Statement 11-207.
April 2020 - a record sales month with 1,850+ units sold, a 17% increase on March 2020 (previous record sales month)380 new patients prescribed LGP products in April (for a.
LGP granted Manufacture Permit by the Office of Drug ControlLGP plans to commence in-house extraction operations, reducing manufacturing costs and improving manufacturing.
MONTRÉAL, Québec, April 27, 2020 (GLOBE NEWSWIRE) -- Elixxer Ltd. (the “Corporation” or “Elixxer”) (TSX-V: ELXR and OTC-QB: ELIXF) announces that, due to logistics and delays caused by the COVID-19 pandemic, it will postpone the filing of its annual consolidated financial statements and related management’s discussion for the 15-month period ended December 31, 2019 (the “Disclosure Documents”). Elixxer is relying on the blanket exemption provided by the Autorité des marchés financiers and similar exemptions provided by the other members of the Canadian Securities Administrators pursuant to which issuers are granted an additional 45 days to complete their regulatory filings. Elixxer anticipates that its Disclosure Documents will be filed on or about June 15, 2020.
MONTRÉAL, April 15, 2020 (GLOBE NEWSWIRE) -- Elixxer Ltd. (ELXR.V) (ELIXF) (FRA 2LQA) (“ELIXXER” or (the “Company”) is pleased to update that its pharmaceutical medical cannabis partner, Little Green Pharma (ASX:LGP) of Australia, has successfully exported their first shipment of medicinal cannabis products for patients into the UK. The products are to be distributed in the UK by Astral Health, a UK-based specialist importer and distributor of medicinal cannabis products and subsidiary of the LYPHE Group.
Freia has added a second line Dermogel Hand Sanitizer with alcohol to meet customer demand. Freia has confirmed sales orders of N95 Facemasks into the European market. Freia has sourced this catalogue of facemasks available for the UK and North American markets.
MONTRÉAL, April 08, 2020 (GLOBE NEWSWIRE) -- Elixxer Ltd. (ELXR.V) (OTC-QB:ELXIF) (FRA 2QLA) (“ELIXXER” or (the “Company”) is pleased to announce that its pharmaceutical partner, Freia launches production of ImmunoV Forte, to improve and protect respiratory function in the human body against airborne infections. Freia is initiating clinical trials on the active ingredients in ImmunoV Forte that aid and protect the human respiratory tract from external environmental attacks such as respiratory viruses, bacteria, smoke and pollution. In being compliant with Canadian Exchange regualators, both Elixxer and Freia are not making any expressed or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
ELIXXER, LTD. (TSX.V: ELXR OTCQB: ELIXF GR: 2LQA) (“ELXR” or the “Company”) is pleased to announce that Little Green Pharma continues to closely monitor progress of the COVID-19 pandemic and provided the following update on its key response activities. Little Green Pharma (LGP) has taken actions to protect the health and welfare of staff, maintain cultivation and manufacturing operations, review its cost base, manage cost exposure and counterparty risk, apply for cost relief and Government assistance where available, and secure supply chains of critical materials and consumables. LGP’s office-based staff have successfully moved to a remote working model, while the cultivation and manufacturing teams continue to operate at their respective facilities in accordance with COVID-19 management procedures.
MONTREAL, March 31, 2020 -- ELIXXER, LTD. (TSX.V: ELXR. OTCQB: ELIXF GR: 2LQA) (“ELXR” or the “Company”) Announces that Ms. Kym No, Controller of Elixxer, Ltd. has been.
The facility expansion was commissioned on time and on budget using state-of-the-art equipment, enhancing the Company’s ability to produce GMP manufactured medicinal cannabis. The expanded cultivation facility will have the capacity to produce sufficient cannabis flower to manufacture more than 110,000 bottles of medicinal cannabis oil per annum, approximately ten times the current production capacity.
MONTRÉAL, March 17, 2020 (GLOBE NEWSWIRE) -- Elixxer Ltd. (the “Corporation” or “Elixxer”) (TSX-V: ELXR and OTC-QB: ELIXF) is pleased to announce that, following receipt of conditional approval from the TSX Venture Exchange, it has now closed its previously announced convertible loan transaction (the “Loan”) with international investors led by YA II PN, Ltd. (the “Lenders”) pursuant to which they have agreed to refinance the principal amount of $US1,183,000 which is outstanding under expiring convertible notes. The Corporation is not receiving any new cash pursuant to the Loan. The Loan has a maturity date of January 1, 2021 (the “Maturity Date”) and bears interest at the rate of 12% per annum.
Freia’s initial launch of 10,000 bottles of Dermogel in Italy, with the first batch of 4,000 bottles has been sold out within 5 days. Freia’s Manufacturing and supply chains are open, and another 34,000 units are being ordered for express delivery into Italy and 50,000 units on order from the UK. Dermogel has been clinically proven to sanitize hands and to be effective in reducing microbial and viral contaminants on the skin.
Little Green Pharma granted expanded Medicinal Cannabis Licence and new Manufacturing Licence. Expanded Medicinal Cannabis Licence covers LGP’s expanded cultivation facility. Manufacturing Licence covers LGP’s new manufacturing facility at which the Company intends to produce cannabis extracts for manufacture into final product form.
MONTRÉAL, March 06, 2020 (GLOBE NEWSWIRE) -- Elixxer Ltd. (the “Corporation” or “Elixxer”) (TSX-V: ELXR and OTC-QB: ELIXF) is pleased to announce that it will enter into an investment agreement (the “Investment Agreement”) with international investors YA II PN, Ltd. and RiverFort Global Opportunities PLC (the “Lenders”) pursuant to which they will loan Elixxer an aggregate amount of US$1,183,000 (the “Loan”). The Loan will have a maturity date of January 1, 2021 (the “Maturity Date”) and will bear interest at the rate of 12% per annum. The principal amount of the Loan may be convertible into common shares of Elixxer (the “Shares”) at the option of the Lenders at a price per Share of CAD$0.05.
Highlights: Little Green Pharma signs three-year purchase agreement with Berlin-based DEMECAN for the sale and export of up to 1,000kg of dried flower or 48,000 units of.
Highlights Little Green Pharma begins trading on the ASX under the symbol LGPLittle Green Pharma signs binding five-year purchase agreement with UK-based Astral Health to.
MONTREAL, Jan. 31, 2020 -- Elixxer Ltd. (the “Corporation” or “Elixxer”) (TSX-V: ELXR and OTC-QB: ELIXF) announces that it has changed its auditor from Ernst & Young LLP.
Elixxer Ltd. (TSX-V: ELXR and OTC-QB: ELXIF) (“ELIXXER” or (the “Company”) has signed an indicative term sheet for a US$12 million convertible loan (the “Loan”) from AD Asset Management LLC (“AD”), a U.S.-based fund management company. Elixxer’s management is reviewing businesses with revenues that exceed US$50 million per year and show scope for expansion.
MONTRÉAL, Jan. 16, 2020 -- Elixxer Ltd. (the “Corporation” or “Elixxer”) (TSX-V: ELXR and OTC-QB: ELXIF) announces that it has granted stock options to purchase a total of.
Little Green Pharma Ltd (“LGP”) has applied to list on the ASX, with a target listing date of February 7th, 2020 under the symbol ‘LGP’. Elixxer is currently the largest shareholder and supports LGP’s expansion plan throughout Australia and international markets into Europe. LGP is currently expanding operations in Australia to increase their current production from 15,000 bottles of medical cannabis oil per year to over 110,000 bottles.
If you own shares in Elixxer Ltd. (CVE:ELXR) then it's worth thinking about how it contributes to the volatility of...
MONTRÉAL, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Elixxer Ltd. (TSX-V: ELXR and OTC-QB: ELXIF) (“ELIXXER”) is pleased to announce that Global Canna Labs has successfully exported 10 kilograms of medical cannabis from Jamaica into Canada. Global Canna is one of the foremost medical cannabis companies in Jamaica. The tier 3 license is one of the largest issued Licensees by the CLA for the cultivation and production of medical cannabis.
MONTREAL, Dec. 04, 2019 -- Elixxer Ltd. (TSX-V: ELXR and OTC-QB: ELXIF) (“ELIXXER”) is pleased to announce that Global Canna Labs has successfully exported 10 kilograms of.
MONTRÉAL, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Elixxer Ltd. (TSXV: ELXR and OTC-QB: ELIXF) (“ELXR”) is pleased to announce that EU pharmaceutical company, Freia Farmaceutici Srl (“Freia”), has completed a full clinical trial, just published on Elsevier’s Food Research International, to demonstrate the efficacy and safety in children of its nutritional supplement Alfalife. Alfalife is now selling in Italy and is in advanced discussions to launch this pharmaceutical product in Eastern Europe, China and Middle East & North Africa (MENA) regions.